← Back

Wire · opportunities

Experimental ALS treatment slows disease progression by 50% in trial

Published

20 November 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at alsnewstoday.com →

◆ Verified

Fusion42 · 20 November 2026 · Fusion42 review

QRL-201, an experimental antisense oligonucleotide therapy by Quralis, slowed ALS disease progression by 50% at a 10 mg dose in a Phase 1/2 trial and prompted FDA clearance to begin a pivotal Phase 3 trial in the U.S. in 2027.

This Wire brief sits within Fusion42's coverage of Biotech, and 3 sources have reported it between 16 Nov 2026 and 20 Nov 2026.

◆ ◆ The Wire takeaway

ALS drug development shifts with Quralis clearing FDA to test QRL-201 in a pivotal trial. You in biotech should track this novel genetic therapy as it opens rare disease markets earlier than usual.

◆ Coverage

3 sources · first reported 16 Nov 2026 · latest 20 Nov 2026

◆ Related on Wire

◆ Topics

Biotechalsbiotechclinical-trialfda-clearancerare-disease